ArkBio Advances AK0406 with China IND Approval
Shanghai, China, August 12, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced that China’s National Medical Products Administration (NMPA)...
NMPA
Advertisement
Laekna Advances LAE002 Toward China Breast Cancer Approval
SHANGHAI, China, August 12, 2026 Laekna announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug...
Alebund Pharmaceuticals Gains China NMPA NDA Acceptance
SHANGHAI, August 7, 2026 Alebund Pharmaceuticals announced that China’s National Medical Products Administration (NMPA) has formally accepted for review...
Adlai Nortye Receives HREC Approval for AN4035 Phase I Trial
SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 3, 2026 Adlai Nortye Ltd. has advanced its oncology pipeline after submitting a...
Argo Biopharma Doses First Patient in BW-41012 Trial
SHANGHAI, China & NEW YORK, July 20, 2026 Argo Biopharma has announced the successful dosing of the first participant...
Advertisements
Antengene and UCB Advance ATG-201 Partnership with $60M Payment
SHANGHAI and HONG KONG, China, July 13, 2026 Antengene has announced the receipt of a USD 60 million upfront...
Hansoh Pharma Reports Positive Phase III Ris-Rez SCLC Results
SHANGHAI, China, July 10, 2026 Hansoh Pharmaceutical Group Co., Ltd. has announced that its Phase III ARTEMIS-008 clinical trial...
Leads Biolabs Secures Priority Review for Opamtistomig
NANJING, China | July 10, 2026 Nanjing Leads Biolabs Co., Ltd. has announced that the Center for Drug Evaluation...
InxMed Publishes Landmark Ifebemtinib NSCLC Trial Results
NANJING, China, July 9, 2026 InxMed Co., Ltd., a clinical-stage biotechnology company focused on overcoming cancer treatment resistance, has...
Aligos Secures $25M Upfront in Greater China Deal
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Aligos Therapeutics has received a $25 million upfront payment from Xiamen Amoytop...
Advertisement
